心擎医疗 magAssist

What 心擎医疗 magAssist does

magAssist (心擎医疗) is a China-based medical device company founded in May 2017 and headquartered in Suzhou, Jiangsu, that develops platform-based extracorporeal life support systems anchored by proprietary full magnetic levitation (maglev) blood pump technology. Its product portfolio comprises MoyoAssist, a fully magnetically levitated extracorporeal ventricular assist device approved by China's NMPA in April 2024 as the first of its kind domestically; NyokAssist, a 9Fr percutaneous ventricular assist device with U.S. FDA Breakthrough Device designation; BreathMo, a portable ECMO system that completed clinical trials in February 2024; and DonorLife, an organ care system co-developed with Wuhan Union Hospital for warm-blood donor heart transport.

The underlying technology stack combines full magnetic levitation rotor design, computational fluid dynamics optimization, and mechatronics integration to reduce hemolysis and thrombosis versus mechanical-bearing pumps, supported by over 400 patent applications (more than 60% invention patents, including PCT filings). MagAssist is led by founder and CEO Dr. Po-Lin Hsu, who holds dual PhDs from Cambridge and RWTH Aachen University, and the founding team originated from RWTH Aachen's Department of Cardiovascular Engineering.

The company operates a B2B medical device go-to-market targeting tertiary hospitals in China, deploying products through direct enterprise sales and clinical KOL partnerships, with academic conference engagement (ASAIO, TCT, ISMCS, ELSO) as the primary demand-generation channel. Revenue derives from device sales plus recurring consumables, with a manufacturing footprint engineered for 40,000 consumables annually under Class 10,000 cleanroom conditions. MoyoAssist consumables have been included in medical insurance reimbursement catalogs across Jiangsu, Zhejiang, Guangdong, and Henan with reimbursement rates up to 97%, supporting broader hospital adoption.

Name

心擎医疗 magAssist

Legal name

magAssist Co., Ltd.

Website

https://en.magassist.tech

Company type

Private

Founded year

2017

Operating status

Operating

Headcount range

11–50 employees

Short description

magAssist develops platform-based extracorporeal life support systems using proprietary magnetic levitation technology, including ventricular assist devices, ECMO, and organ care systems sold to tertiary hospitals for cardiovascular patients in China.

Ownership category

akta.pro rank

Product category

Mechanical Circulatory Support Medical Devices

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)

SIC

Electromedical & Electrotherapeutic Apparatus (3845), Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Mechanical Circulatory Support (VAD, IABP, ECMO) (HLAHAFAG)

akta.pro secondary industry

Cardiac Assist & Heart Failure Therapies (Implantables, Neuromodulation) (HLAHAFAL)

Keywords

• Extracorporeal ventricular assist devices
• Mechanical circulatory support
• Magnetic levitation blood pumps
• Extracorporeal membrane oxygenation
• Organ care systems

Headquarters

HQ city

Suzhou

HQ country

China

HQ region

Asia

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Supply Chain, Operations, Personnel, Marketing or Sales

Revenue model

1. Medical Device Sales: Sale of extracorporeal ventricular assist devices (VADs), percutaneous VADs, ECMO systems, and consumables to hospitals. MoyoAssist consumables were included in Jiangsu Province and Suzhou City reimbursement catalogs.
2. Product Consumables: Recurring consumables revenue from ventricular assist device and ECMO consumables. Clean manufacturing designed to meet annual production line of 40,000 consumables.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels6 records

Core offering

magAssist develops and manufactures platform-based external life support systems built around full magnetic levitation (maglev) blood pump technology. Its commercial portfolio spans extracorporeal ventricular assist devices (MoyoAssist), percutaneous ventricular assist devices (NyokAssist), extracorporeal membrane oxygenation systems (BreathMo), and an organ care system (DonorLife), sold to tertiary hospitals and cardiovascular centers for short- to mid-term circulatory support of critically ill patients.

Product overview

magAssist develops a platform-based portfolio of external life support systems centered around mechanical circulatory support. The major product lines include MoyoAssist® (fully magnetically levitated extracorporeal VAD providing short- to mid-term circulatory support for cardiogenic shock, approved by China NMPA), NyokAssist™ (9Fr percutaneous VAD for short-term high-risk PCI support, FDA Breakthrough Device designated), BreathMo® (magnet levitated ECMO platform for cardiac and pulmonary assistance), and DonorLife™ (warm blood organ transport system). The platform is built on unified control architecture enabling modular integration across catheterization laboratories, operating rooms, and intensive care units.

Differentiator

Problem solved

Functional benefit

Brands

• MoyoAssist: Extracorporeal Ventricular Assist Device - China's first fully magnetically levitated extracorporeal VAD.
• NyokAssist
• BreathMo
• DonorLife

Products and services

• MoyoAssist® Extracorporeal Ventricular Assist Device A fully magnetically levitated extracorporeal ventricular assist device providing short- to mid-term circulatory support for up to 30 days. Designed for patients with acute cardiogenic shock, post-cardiotomy cardiogenic shock, bridge to transplantation, and bi-ventricular heart failure. Features CFD-optimized flow path and a console under 10kg with 2+ hour battery life. China NMPA-approved.
• NyokAssist™ Percutaneous Ventricular Assist Device A 9Fr collapsible percutaneous ventricular assist device for short-term circulatory support during high-risk PCI procedures. External motor design reduces cost and eliminates heat-related blood damage. FDA Breakthrough Device designation and NMPA Innovative Medical Device designation.
• BreathMo® Extracorporeal Membrane Oxygenation (ECMO) A next-generation portable ECMO system based on the unified magnetically levitated pump platform, supporting both cardiac and pulmonary assistance. Full magnetic levitation achieves or surpasses international standards in hemolysis, clotting, gas exchange, and oxygenator pressure drop.
• DonorLife™ Organ Care System An organ care system enabling warm blood perfusion and oxygenated transport of donor hearts, jointly developed with Wuhan Union Hospital. Extends preservation time beyond 12 hours compared with traditional cold ischemia methods.

Quantifiable outcome

• 74% successful weaning rate from MoyoAssist support
• +3 more outcomes

Named customers5 records

Segments3 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

Five partnerships are on record, tiered core and minor.

• Soochow UniversitycoreStrategic or Co-development Partner · 1 January 2025magAssist was founded through Soochow University's industry-academia-research entrepreneurship support program. Dr. Po-Lin Hsu serves as professor and doctoral advisor at Soochow University. Long-term collaboration to build joint laboratory on smart artificial organs.
• Beijing Anzhen Hospital (Capital Medical University)coreStrategic or Co-development Partner · 22 March 2022Joint ECMO R&D project partnership. Anzhen Hospital is home to Beijing Extracorporeal Life-support Quality Control and Improvement Center. Collaboration to develop ECMO equipment and consumables with fully independent intellectual property rights.
• Wuhan Union HospitalcoreStrategic or Co-development Partner · 1 July 2021Joint development of Organ Care System (DonorLife). Successfully completed first domestic warm blood transfusion of waste animal hearts. System can realize heart transportation while being oxygenated with blood with storage time expected to exceed 12 hours.
• Academician Junbo Ge's team (Zhongshan Hospital, Fudan University)coreStrategic or Co-development Partner · 1 July 2021Joint development of percutaneous ventricular assist device (NyokAssist). Ge Junbo's team is a leading Chinese cardiology expert team. Collaboration on interventional ventricular assist device development.
• GuoQian Medical TechnologyminorStrategic or Co-development Partner · 1 January 2021Collaboration on medical device engineering transformation through magAssist Laboratory.

Scale indicators8 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Berlin Heart: Specialist in extracorporeal ventricular assist devices (EXCOR) for pediatric and adult patients, sharing magAssist's focus on extra-VAD platforms for short-to-mid-term circulatory support and bridge-to-transplant indications.
• SynCardia Systems: Developer of the SynCardia Total Artificial Heart, a direct mechanical circulatory support device targeting end-stage heart failure and bridge-to-transplant — overlapping with magAssist's MoyoAssist BTT indication and end-stage heart failure patient segment.
• LivaNova: Develops advanced circulatory support including the TandemLife platform (now part of LivaNova), spanning ECMO and temporary VAD use cases that overlap with MoyoAssist and BreathMo. Both serve tertiary cardiovascular centers for short-term mechanical support.
• Terumo: Major player in ECMO systems with the Terumo System 1 and related oxygenators/pumps, directly competing with magAssist's BreathMo. Both target cardiac and pulmonary extracorporeal support in tertiary hospital settings.
• Abiomed (Johnson & Johnson MedTech): Maker of the Impella family of percutaneous ventricular assist devices — the most direct competitor to magAssist's NyokAssist pVAD for high-risk PCI support. Both target the same interventional cardiology use case with catheter-based temporary circulatory support.

Broad incumbents

• Medtronic: Holds legacy position in extracorporeal MCS (HVAD program) and broad ECMO offerings. Competes head-to-head with magAssist across both Extra-VAD and ECMO indications in hospital procurement cycles globally.
• Fresenius Medical Care (Xenios): Through its Xenios subsidiary, Fresenius offers i-cor and cardiopulmonary support systems that compete with magAssist's ECMO portfolio. As a global dialysis and critical-care giant, Fresenius has the distribution scale and capital depth magAssist lacks.
• Abbott: Global leader in mechanical circulatory support with HeartMate 3 LVAD and CentriMag/ECMO platforms, serving the same tertiary-hospital cardiology and cardiac surgery markets that magAssist targets. Its installed base, clinical evidence, and physician relationships set the competitive bar magAssist must clear, particularly in international expansion.

Regional players

• Shenzhen Coreway Technology: Chinese medical device company focused on mechanical circulatory support and artificial heart systems. As a domestic China-based peer with overlapping product positioning, it competes with magAssist in the same tertiary-hospital procurement environment, though typically without the maglev differentiation.
• BrioHealth Solutions (永仁心): Chinese developer of ventricular assist devices (EVAHEART) approved in China. Competes with magAssist in the same domestic LVAD/BTT market, making it the most direct domestic peer for evaluating China's VAD adoption trajectory.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/channel/UCOqp_LJeDIpk-HiHe4TpZCQ
• Facebookm.facebook.com/magAssist.Co
• LinkedInlinkedin.com/company/magassistcn

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about 心擎医疗 magAssist